This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Eisai Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

-5.1%

Tasso di crescita degli utili

-5.1%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore	7.3%
Tasso di crescita dei ricavi	4.7%
Rendimento del capitale proprio	3.4%
Margine netto	3.6%
Ultimo aggiornamento sui guadagni	31 Dec 2022

Aggiornamenti sulle prestazioni recenti

Nessun aggiornamento

Recent updates

Ripartizione dei ricavi e delle spese

Come Eisai guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

MUN:EII0 Ricavi, spese e utili (JPY Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
31 Dec 22	737,098	26,705	373,875	169,848
30 Sep 22	752,500	32,233	382,752	173,324
30 Jun 22	741,594	32,690	374,428	168,422
31 Mar 22	756,226	47,954	356,847	171,738
31 Dec 21	712,935	57,311	317,150	165,418
30 Sep 21	691,250	62,508	293,153	162,699
30 Jun 21	679,253	59,855	282,369	161,584
31 Mar 21	645,942	42,119	272,568	150,299
31 Dec 20	707,888	93,682	271,476	145,248
30 Sep 20	713,400	120,571	261,973	139,628
30 Jun 20	707,203	124,523	253,516	141,217
31 Mar 20	695,621	121,767	248,554	140,116
31 Dec 19	661,646	96,659	244,091	146,367
30 Sep 19	631,974	57,725	239,503	147,863
30 Jun 19	643,531	72,747	233,180	140,143
31 Mar 19	642,834	63,386	223,798	144,844
31 Dec 18	627,367	63,714	212,469	139,100
30 Sep 18	625,106	65,679	195,229	138,461
30 Jun 18	611,499	54,347	186,198	140,514
31 Mar 18	600,054	51,845	179,915	139,579
31 Dec 17	569,814	29,048	178,312	134,955
30 Sep 17	554,276	30,269	178,090	123,639
30 Jun 17	544,027	29,425	176,249	119,503
31 Mar 17	539,097	39,358	175,633	112,478
31 Dec 16	530,696	55,031	175,240	110,471
30 Sep 16	542,313	71,812	178,825	114,420
30 Jun 16	545,602	69,227	182,036	115,750
31 Mar 16	547,922	54,933	188,227	122,307

This company listing is no longer active

Eisai Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Recent updates

Eisai Co., Ltd. and Biogen Inc. Announce Lecanemab Receives Priority Review Status in Japan

Eisai Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease

Eisai Co., Ltd. Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan

Eisai Co., Ltd. and Biogen Inc. Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe

Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

Eisai Initiates BLA Submission of Data for Lecanemab in China

Eisai Presents Results of Lecanemab Phase 3 Confirmatory Clarity AD Study for Early Alzheimer's Disease at CTAD Conference

Eisai to Present Latest Data on Fycompa (Perampanel) CIII at the 76th American Epilepsy Society (AES) Annual Meeting

DKSH Holding AG (SWX:DKSH) signed an agreement to acquire Two pharma brands of Eisai.

Eisai Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Eisai Announces Real-World Evidence on the Clinical Effectiveness of LENVIMA® (lenvatinib) Monotherapy for the Treatment of Patients with Radioiodine-Refractory Differentiated Thyroid Cancer

Eisai Co. and Biogen Announce Positive Topline Results from Eisai's Large Global Phase 3 Confirmatory Clarity AD Clinical Trial of Lecanemab

Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

Eisai Presents New Data from Its Oncology Portfolio and Pipeline At ESMO Congress 2022

Eisai Presents New Data for Lecanemab (Ban2401) At Alzheimer's Association International Conference

Merck & Co., Inc. and Eisai Co., Ltd. Provides Update on Phase 3 LEAP-002 Trial

Eisai Co., Ltd. and Biogen Inc. Announces U.S. Food and Drug Administration Accepted the Biologics License Application

Global Coalition for Adaptive Research Announces the Discontinued Evaluation of Eritoran in REMAP-COVID

Eisai Co., Ltd., Annual General Meeting, Jun 17, 2022

Eisai Co., Ltd., Annual General Meeting, Jun 17, 2022

Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway

Ripartizione dei ricavi e delle spese

Storia dei guadagni e delle entrate

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Rendimento del capitale proprio

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate